Xenetic Biosciences (XBIO) Cash from Investing Activities (2014 - 2019)
Xenetic Biosciences' (XBIO) quarterly Cash from Investing Activities came in at $2000.0 in Q1 2019, down 91.11% on a QoQ basis from $22500.0 in Q3 2018.
Xenetic Biosciences (XBIO) Cash from Investing Activities (2014 - 2019) Analysis & Trends
Xenetic Biosciences (XBIO) has 6 years of Cash from Investing Activities data on file, last reported at $2000.0 in Q1 2019.
- Quarterly Cash from Investing Activities changed N/A year-over-year to $2000.0 in Q1 2019, while the trailing twelve-month figure through Dec 2019 was $2000.0 (down 91.11% YoY) and the FY2022 annual result came in at -$500000.0, changed N/A from the prior year.
- Cash from Investing Activities fell to $2000.0 in Q1 2019, from $22500.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $22500.0 in Q3 2018 to a low of -$14613.0 in Q1 2016.
- A 5-year average of $466.2 and a median of -$831.5 in 2015 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2015 — Cash from Investing Activities soared 154.36% — and 2016, when it sank 334.0%.
- Tracing XBIO's Cash from Investing Activities over 5 years: stood at $1637.0 in 2015, then tumbled by 233.17% to -$2180.0 in 2016, then sank by 75.92% to -$3835.0 in 2017, then soared by 686.7% to $22500.0 in 2018, then sank by 91.11% to $2000.0 in 2019.
- The last three Cash from Investing Activities figures came in at $2000.0 (Q1 2019), $22500.0 (Q3 2018), and -$3835.0 (Q2 2017), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Xenetic Biosciences | 8.01 Mn | 1.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 2,000.00 |
| Mar 31, 2019 | 2,000.00 |
| Sep 30, 2018 | 22,500.00 |
| Sep 30, 2018 | 22,500.00 |
| Jun 30, 2017 | -3,835.00 |
| Jun 30, 2017 | -3,835.00 |
| Mar 31, 2017 | -5,429.00 |
| Mar 31, 2017 | -5,429.00 |
| Dec 31, 2016 | -2,180.00 |
| Dec 31, 2016 | -2,180.00 |
| Mar 31, 2016 | -14,613.00 |
| Mar 31, 2016 | -14,613.00 |
| Dec 31, 2015 | 1,637.00 |
| Dec 31, 2015 | 1,637.00 |
| Sep 30, 2015 | -1.00 |
| Sep 30, 2015 | -1.00 |
| Jun 30, 2015 | -1,662.00 |
| Jun 30, 2015 | -1,662.00 |
| Mar 31, 2015 | 6,245.00 |
| Mar 31, 2015 | 6,245.00 |